New Delhi:Strides Pharma Science Ltd has posted a sharp 82 percent rise in consolidated net profit at Rs 131.52 crore for the quarter ended September 30, 2025, on the back of robust revenue growth in other regulated markets and lower expenses. The Bengaluru-based drugmaker had reported a consolidated net profit of Rs 72.3 crore in the same quarter last year. Consolidated revenue from operations increased to Rs 1,220.83 crore from Rs 1,166.93 crore a year earlier, while total expenses edged down to Rs 1,085.03 crore from Rs 1,104.61 crore. Commenting on the performance,Strides Pharma ScienceMD & Group CEO, Badree Komandur said, "Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the 'other regulated markets'." In an investor presentation, the company said in Q2 FY26 'other regulated markets' revenue was at USD 44 million, at a growth of 16 per cent. All regulated markets excluding the US form part of the Other Regulated Markets. In the US market Q2FY26 revenue was at USD 73 million, up 2 per cent YoY despite intense competition in recent launches from new entrants, PTI reported. Growth markets, including Africa operations and new geographies of LATAM (Latin America), MENA (Middle East and North Africa) and APAC (Asia-Pacific) registered revenue of USD 17 million, up 7 per cent, it added. Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor- funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries.